ARUP's Laboratory Test Directory
| 0080392: Cancer Antigen 27.29 |
| Test Mnemonic: CA27.29 | |
|
Methodology: Chemiluminescent Immunoassay
Performed: Sun-Sat Reported: Within 24 hours |
| Specimen Required: | |
|
Collect: One 4 mL plain red or SST.
Transport: 1 mL serum, frozen. (Min: 0.5 mL) Submit specimen in an ARUP Standard Transport Tube. Pediatric Collection/Transport: 0.3 mL serum, frozen. Remarks: Allow specimen to clot completely at room temperature. Separate serum from cells ASAP. Unacceptable Conditions: Plasma. Stability: After separation from cells: Ambient: 8 hours; Refrigerated: 2 days; Frozen: 3 months |
|
| Reference Interval: |
| 0-40 U/mL |
| Interpretive Data: | |
|
The Siemens Advia Centaur CA 27.29 chemiluminescent immunoassay is used. Results obtained with different assay methods or kits cannot be used interchangeably. The CA 27.29 assay is intended for use as an aid in monitoring patients previously treated for Stage II or III breast cancer. Serial testing in patients who are clinically free of disease should be used in conjunction with other clinical methods used for the early detection of cancer recurrence. The test is also intended for use as an aid in the management of breast cancer patients with metastatic disease by monitoring the progression or regression of disease in response to treatment. Patients with confirmed breast carcinoma frequently have CA 27.29 levels within the reference interval. Elevated levels of CA 27.29 can be observed in patients with nonmalignant diseases. Therefore, this result cannot be interpreted as absolute evidence of the presence or absence of malignant disease and should always be used in conjunction with other diagnostic procedures, including information from the patient's clinical evaluation.
|
| CPT Code(s): | |
| 86300 |